Loading…
Loading…
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) today announced that it has withdrawn its previously filed Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission. After careful review of current market conditions and deal terms, management and the Board of Directors concluded that proceeding with the offering at this time would not reflect the value DSS believes it is building for shareholders.
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepte
ROCHESTER, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced that its annual report (10-K) for the fiscal year ending December 31, 2025, filed on March 31, 2026, includes an audit opinion from HTL International LLC. that contains a "going concern" qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company's financial statements for the year ended December 31, 2025.
ROCHESTER, N. Y. , April 15, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) today issued the following letter to shareholders from the Interim CEO, Jason Grady, highlighting the Company's operational progress, financial improvements, and strategic initiatives. Dear Fellow Shareholders, Over the past six months, our stock performance has not fully reflected the progress we have made inside DSS.
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $1.0 million, before deducting underwriting fees and other offering expenses payable by the Company.
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $1.0 million, before deducting underwriting fees and other offering expenses payable by the Company.
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including packaging, wealth management, and biohealth innovation, today announced that it has commenced a public offering to offer and sell shares of its Common Stock.
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating across diverse industries including packaging, real estate, and biomedical innovation, today announced financial results for the first quarter of 2025, highlighting meaningful progress in its financial repositioning and a strong foundation for corporate execution in the coming quarters.